Stockholders approve amendment to CalciMedica 2023 equity plan, adding 600,000 shares

CalciMedica, Inc.

Stockholders elected all three Class I director nominees: Leheny, Roberts, Guerard with over 9.5M votes each.
Ratification of Baker Tilly as independent auditor for FY 2025 passed with 12.3M votes for, 135K against.
Amendment to 2023 Equity Incentive Plan approved (8.9M for, 923K against), increasing authorized shares by 600,000.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.